Assignee
NANTCELL INC
US·41 granted patents·32 pending applications·27 citations·filing 2017–2025
Top patents by PatentIndex Score
73 records- 0197US11554167B2Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancerNANTCELL INC·Filed 2022·Granted Jan 17, 2023·3 cites·9 claims
- 0296US12016911B2Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancerNANTCELL INC·Filed 2023·Granted Jun 25, 2024·1 cites·20 claims
- 0396US11364291B1Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancerNANTCELL INC·Filed 2020·Granted Jun 21, 2022·3 cites·14 claims
- 0495US11857612B2Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancerNANTCELL INC·Filed 2022·Granted Jan 2, 2024·1 cites·17 claims
- 0592US12516093B2Recombinant erIL-15 NK cellsNANTCELL INC·Filed 2022·Granted Jan 6, 2026·1 cites·15 claims
- 0691US12156901B2Treatment of immunosuppressed subjectsNANTCELL INC·Filed 2023·Granted Dec 3, 2024·1 cites·15 claims
- 0790US12168048B2Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancerNANTCELL INC·Filed 2024·Granted Dec 17, 2024·0 cites·18 claims
- 0890US11229668B2Maximizing T-cell memory and compositions and methods thereforNANTCELL INC·Filed 2018·Granted Jan 25, 2022·3 cites·20 claims
- 0990US2025064911A1Bacillus calmette-guerin (bcg) and antigen presenting cells for treatment of bladder cancerNANTCELL INC·Filed 2024·Application pending·0 cites
- 1086US11701408B2Treatment of immunosuppressed subjectsNANTCELL INC·Filed 2019·Granted Jul 18, 2023·2 cites·6 claims
- 1186US11311603B2HIV treatment compositions and methodsNANTCELL INC·Filed 2019·Granted Apr 26, 2022·2 cites·15 claims
- 1286US11154597B2Sequence arrangements and sequences for neoepitope presentationNANTCELL INC·Filed 2017·Granted Oct 26, 2021·2 cites·4 claims
- 1385US12303477B2HIV treatment compositions and methodsNANTCELL INC·Filed 2023·Granted May 20, 2025·0 cites·14 claims
- 1485US12285481B2Methods for the treatment of COVID-19 comprising administering replication-defective adenoviruses encoding the SARS-CoV-2 spike glycoprotein and modified nucleocapsid proteinNANTCELL INC·Filed 2023·Granted Apr 29, 2025·0 cites·12 claims
- 1584US12580056B2Production and delivery tracking and sample verification of patient-specific therapeuticsNANTCELL INC·Filed 2024·Granted Mar 17, 2026·0 cites·20 claims
- 1684US12303552B2Treatment of immunosuppressed subjectsNANTCELL INC·Filed 2024·Granted May 20, 2025·0 cites·18 claims
- 1784US11662938B2Object storage and access management systems and methodsNANTCELL INC·Filed 2021·Granted May 30, 2023·2 cites·20 claims
- 1883US12050802B2Object storage and access management systems and methodsNANTCELL INC·Filed 2023·Granted Jul 30, 2024·1 cites·22 claims
- 1983US11779637B2Targeted neoepitope vectors and methods thereforNANTCELL INC·Filed 2018·Granted Oct 10, 2023·1 cites·10 claims
- 2083US11590217B2Neoepitope vaccine and immune stimulant combinations and methodsNANTCELL INC·Filed 2019·Granted Feb 28, 2023·1 cites·6 claims
- 2182US12427184B2Treatment of immunosuppressed subjectsNANTCELL INC·Filed 2025·Granted Sep 30, 2025·0 cites·13 claims
- 2282US12112838B2Production and delivery tracking and sample verification of patient-specific therapeuticsNANTCELL INC·Filed 2023·Granted Oct 8, 2024·0 cites·20 claims
- 2382US11894109B1Production and delivery tracking and sample verification of patient-specific therapeuticsNANTCELL INC·Filed 2019·Granted Feb 6, 2024·2 cites·18 claims
- 2479US12311018B2Targeted neoepitope vectors and methods thereforNANTCELL INC·Filed 2023·Granted May 27, 2025·0 cites·10 claims
- 2579US2025118436A1Deep Learning Models For Tumor EvaluationNANTCELL INC·Filed 2024·Application pending·0 cites
- 2677US12487241B2Rapid verification of virus particle production for a personalized vaccineNANTCELL INC·Filed 2022·Granted Dec 2, 2025·0 cites·13 claims
- 2777US11786577B2HIV treatment compositions and methodsNANTCELL INC·Filed 2021·Granted Oct 17, 2023·0 cites·20 claims
- 2877US2025255840A1HIV Treatment Compositions And MethodsNANTCELL INC·Filed 2025·Application pending·0 cites
- 2976US12527865B2haNK cetuximab combinations and methodsNANTCELL INC·Filed 2022·Granted Jan 20, 2026·0 cites·14 claims
- 3076US12297247B2Fusion molecules of CTLA4 and IL-15NANTCELL INC·Filed 2023·Granted May 13, 2025·0 cites·12 claims
- 3175US11684668B2Replication-defective adenoviruses comprising nucleic acids encoding SARS-CoV-2 s glycoprotein and modified N protein comprising an endosomal targeting sequenceNANTCELL INC·Filed 2020·Granted Jun 27, 2023·0 cites·16 claims
- 3275US11439697B2Nant cancer vaccineNANTCELL INC·Filed 2021·Granted Sep 13, 2022·0 cites·20 claims
- 3375US2024193784A1Systems And Methods For Performing Segmentation Based On Tensor InputsNANTCELL INC·Filed 2024·Application pending·0 cites
- 3474US11564980B2Tumor treatment method with an individualized peptide vaccineNANTCELL INC·Filed 2019·Granted Jan 31, 2023·1 cites·13 claims
- 3572US2023145817A1Neoepitope vaccine and immune stimulant combinations and methodsNANTCELL INC·Filed 2023·Application pending·0 cites
- 3670US2024354026A1Object Storage And Access Management Systems And MethodsNANTCELL INC·Filed 2024·Application pending·0 cites
- 3769US12571003B2Electroporation with active compensationNANTCELL INC·Filed 2024·Granted Mar 10, 2026·0 cites·5 claims
- 3868US11510982B2HaNK cetuximab combinations and methodsNANTCELL INC·Filed 2018·Granted Nov 29, 2022·0 cites·12 claims
- 3967US11573230B2Rapid verification of virus particle production for a personalized vaccineNANTCELL INC·Filed 2019·Granted Feb 7, 2023·0 cites·12 claims
- 4065US2022257649A1Combination therapies for multiple myelomaNANTCELL INC·Filed 2019·Application pending·0 cites
- 4164US11318189B1IL-15 agonist drug combinations for immune therapyNANTCELL INC·Filed 2021·Granted May 3, 2022·0 cites·26 claims
- 4263US12224064B2Deep learning models for tumor evaluationNANTCELL INC·Filed 2021·Granted Feb 11, 2025·0 cites·16 claims
- 4362US12531134B2HLA clusters, global frequencies, and binding across SARS-CoV-2 variationNANTCELL INC·Filed 2022·Granted Jan 20, 2026·0 cites·30 claims
- 4462US2025230211A1Fusion Molecules Of CTLA4 And IL-15NANTCELL INC·Filed 2025·Application pending·0 cites
- 4562US2023034802A1Nant Cancer VaccineNANTCELL INC·Filed 2022·Application pending·0 cites
- 4661US11941813B2Systems and methods for performing segmentation based on tensor inputsNANTCELL INC·Filed 2020·Granted Mar 26, 2024·0 cites·19 claims
- 4760US2025161412A1Combination therapies for multiple myelomaNANTCELL INC·Filed 2025·Application pending·0 cites
- 4860US2024327492A1Modified T Cell Receptors For The Prevention And Treatment Of Viral Infections And CancerNANTCELL INC·Filed 2022·Application pending·0 cites
- 4960US2023218743A1Peptide Therapeutics Against SARS-COV-2 Spike ProteinNANTCELL INC·Filed 2022·Application pending·0 cites
- 5058US2022056542A1Rapid Viral Diagnostic TestNANTCELL INC·Filed 2021·Application pending·0 cites
Showing the top 50 of 73 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when NANTCELL INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →